MarketPeel
Insider Trading Intelligence
CR

Charles S. Ryan

QNCX
PRESIDENT · QUINCE THERAPEUTICS, INC. · CIK 0001624830
FILING MIX · LIFETIME62%/38%
BUYS
8
SELLS
5
TOTAL VALUE
$41.5K
COMPANIES
2
ACTIVE SINCE
Nov 2020
HOLDINGS NOW
200,000
AVG SELL PX
TRADE KIND
SHOWING 13 / 13
Trades · vs SPY
Loading price series…
Performance · forward returns vs SPY
1 backtested trades · 8 horizons · 1 pendingHow are these numbers computed? →
Forward-return performance of every backtestable P/S trade by Charles S. Ryan, measured at 8 horizons from 7 days to 2 years. Deduped per economic event so co-filings count once. Excess return = trade return minus SPY return over the same window.
HORIZONTRADESWIN RATEINSIDER RETURNSPY RETURNMEAN EXCESSMEDIAN EXCESST-STAT
7d1+100.00%+13.12%+0.51%+12.60%+12.60%
14d1+100.00%+13.61%-1.19%+14.79%+14.79%
30d1+100.00%+24.59%+2.20%+22.39%+22.39%
60d1+100.00%+30.33%+4.96%+25.37%+25.37%
90d1+100.00%+186.88%+5.59%+181.29%+181.29%
180d1+100.00%+129.51%+9.83%+119.68%+119.68%
1y1+100.00%+2572.13%+15.29%+2556.84%+2556.84%
2y1(1 pending)
How to read this: Insider Returnis the average raw return of the filer's trades over the horizon. SPY Return is what SPY did over those same windows — reference only, not a comparison. The headline alpha number is Mean Excess = Insider − SPY; green means the filer beat SPY, red means they trailed it. Win rate is the share of individual trades where the filer beat SPY. T-statvalues above 2 mean the alpha is unlikely to be chance given the sample size. "Pending" counts trades where the horizon hasn't elapsed yet; their stats are not included in the row average.
Holdings over time
QNCX · 200,000 shares · as of Jan 23, 2026
0136,250272,500408,750545,000202420252026SHARES HELD
Trading cadence · quarterly flow
BUY SELL
2020
2021
2021
2021
2021
2022
2022
2022
2022
2023
2023
2023
2023
2024
2024
2024
2024
2025
2025
2025
2025
2026
FLOW · 8 buys / 5 sellsCOVERAGE · 22 quarters
Form 4 filings · all activity
COMPANYTYPESHARESPRICEVALUEHELD AFTERTRADE DATEFILEDDETAILS
QNCX
QUINCE THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
200,000200,000Jan 23, 2026Jan 23, 2026View →
QNCX
QUINCE THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
7,548$0.13$9447,548Jun 18, 2025Jun 20, 2025View →
QNCX
QUINCE THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
7,548$1.20$9.1K130,009Jun 18, 2025Jun 20, 2025View →
QNCX
QUINCE THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
300,000300,000Jan 28, 2025Feb 11, 2025View →
QNCX
QUINCE THERAPEUTICS, INC.
PURCHASE
PRESIDENT
48,387$0.65$31.5K122,461Aug 20, 2024Aug 22, 2024View →
QNCX
QUINCE THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
145,000145,000Feb 1, 2024Feb 1, 2024View →
QNCX
QUINCE THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
545,000545,000Sep 1, 2023Sep 6, 2023View →
NTRP
NEXTTRIP, INC.
SALE
150,0000Dec 1, 2020Dec 3, 2020View →
NTRP
NEXTTRIP, INC.
SALE
40,0000Dec 1, 2020Dec 3, 2020View →
NTRP
NEXTTRIP, INC.
SALE
79,0970Dec 1, 2020Dec 3, 2020View →
NTRP
NEXTTRIP, INC.
SALE
130,6800Dec 1, 2020Dec 3, 2020View →
NTRP
NEXTTRIP, INC.
SALE
157,9180Dec 1, 2020Dec 3, 2020View →
NTRP
NEXTTRIP, INC.
PURCHASEGRANT
Stock grant
40,00040,000Nov 24, 2020Nov 27, 2020View →
Other insiders · QNCX
Loading peer insiders…
About this filer
CIK 0001624830
ROLE
PRESIDENT
PRIMARY
QNCX
COMPANIES
2
ACTIVE SINCE
Nov 2020
MARKETPEEL · /INSIDER/0001624830DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE
FREE · DAILY · 6 AM ET

One short email. Insider buys, congressional trades, and plain-English analysis.

Feedback